
Episode 153 - September 5, 2025
On this week’s episode, hosts Paul Matteis, Sam Fazeli, John Maraganore, and Graig Suvannaveijh kick off the discussion with a more positive look at the sector and some of the fundamental factors at play. The group then shares an overview of Sanofi’s 10% stock fall on the back of positive Phase 3 eczema data with worries about the Dupixent patent expiry. The discussion then turns to Insmed, a company that has had a monster year with the stock up 100% and a market cap of over $30 billion market. On the data front, the group highlights ApoC3 data from Ionis and Arrowhead at the European Society of Cardiology Congress 2025, which leads into a discussion around ASO versus RNAi. With multiple obesity readouts in recent weeks, the group theorizes on whether obesity is a zero sum game. It’s a big year ahead for AD readouts and the hosts summarizes some important catalysts on the horizon. Other discussion topics include the launch of Corsera Health for cardiovascular prevention, Trump’s Truth Social post on vaccine data, RFK Jr in front of congress, and public concern around access to vaccines. This episode aired on September 5, 2025.
Publisher
Biotech Hangout
Link
podcasters.spotify.com/pod/show/biotechhangout/episodes/Episode-153---September-5--2025-e37rhda
Published
September 5, 2025
Duration
1h 1m
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
Biotech Hangout
@biotechhangout
#september #lifesciences
